All In Biotech

Drug Trial Radar · NCT06693440

The Immune Assessment of PD-1 Antibody Therapy in Tumor

The Immune Assessment of PD-1 Antibody Therapy in Tumor - A Case-Control Study

Last checked: Nov 20, 2026Latest source record: Nov 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

3,000

Planned (sponsor's estimate)

Start

Jul 1, 2021

Primary completion

Nov 13, 2027

Study completion Nov 13, 2030

Sponsor

Lead sponsor
Quanli GaoGovernment (non-federal)
Sponsor type
Government (non-federal)
First posted
Nov 18, 2024

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This retrospective study will leverage previous immune function monitoring results in conjunction with clinical case data at this medical center.

Conditions

  • Efficacy, Team
  • Adverse Event

Interventions

  • PD-1 InhibitorsDrug

    Patients received PD-1 inhibitors mono- or combined therapy in real-world clinical practice

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rateTime frame: 6 months
  2. Adverse eventsTime frame: 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.